ZyVersa is well positioned in the rapidly emerging inflammasome space with a highly differentiated inflammasome inhibitor, IC 100, which has potential to treat a broad range of inflammatory diseases IC 100 uniquely targets ASC to inhibit multiple types of inflammasomes, and thereby acts independently of the triggers and sensors that cause inflammatory diseases
| WESTON, Fla., March 3, 2021 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and President, is an invited speaker at the H.C. Wainwright Global Life Sciences Conference. The conference is being held virtually March 9-10, 2021. Mr. Glover’s presentation will highlight progress in advancing development of ZyVersa’s inflammasome inhibitor IC 100, and Phase 2a-ready VAR 200, a novel candidate for orphan renal disease, FSGS.
To learn more about ZyVersa’s novel inflammasome inhibitor, please schedule a meeting via the H.C. Wainwright Portal. Mr. Glover’s presentation will be available to registered conference attendees for on-demand viewing beginning Tuesday, March 9, 2021, at 7:00 AM EST. To learn more about ZyVersa and its novel inflammasome inhibitor IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease, please schedule a 1 on 1 virtual meeting with ZyVersa using the conference portal. About ZyVersa Therapeutics, Inc. ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome inhibitor with potential to treat multiple inflammatory diseases, and phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS). For more information, please visit www.zyversa.com.
SOURCE ZyVersa Therapeutics, Inc. |
View original content to download multimedia:
